ReviewJournal of translational medicine2026
The importance of mitochondria and mitochondrial calcium signaling in health and disease: an updated outlook on inflammation.
Review in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Modulating Ubiquinone Biosynthesis Rescues Mitochondrial Dysfunction by Genetic Interaction in a Phosphatidylethanolamine (PE)-Deficient Disease Model.Antioxidants (Basel, Switzerland) · 2026Article
- Ginkgolide B Attenuates 6-Hydroxydopamine-Induced Cellular Damage and Modulates Oxidant-Evoked CaCurrent issues in molecular biology · 2026Article
- The Gut Microbiome as a Mechanistic Link Between the Planetary Health Diet and Healthy Aging.Nutrients · 2026Review
- Review
- Mitochondria Meet the Lung Microbiome: A Bidirectional Dialogue in Inflammation and Respiratory Diseases.Biomedicines · 2026Review
- Review
- Mitochondrial Dynamics and SLC25 Transporters in Neurodegeneration: From Mechanisms to Therapeutic Opportunities.Biomolecules · 2026Review
- Dynamin-Related Protein 1 (Drp1) in Inflammatory Bowel Disease: Molecular Pathways Connecting Mitochondrial Dynamics with Intestinal Inflammation and Homeostasis.International journal of molecular sciences · 2026Review
- Sarcopenia and sepsis fuel a self-perpetuating cycle of immunometabolism decline.Frontiers in immunology · 2026Review
- Preoperative electrolyte-based metabolic biomarkers for prognostic assessment in gastric cancer: a multicenter study.Frontiers in endocrinology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMitochondria are central regulators of cellular bioenergetics, calcium homeostasis and apoptosis. Beyond these classical roles, emerging evidence highlights their pivotal involvement in inflammation and related disease progression. Under physiological conditions, mitochondria sustain metabolism and signaling; however, when dysfunctional, they can release mitochondrial damage-associated molecular patterns, such as mitochondrial DNA, reactive oxygen species, cardiolipin and ATP, into the intra- or extracellular environment. MAIN BODY: The release of these mitochondrial components activates innate immune receptors and inflammasomes, thereby initiating or sustaining inflammatory cascades implicated in aging and a broad range of diseases, including cancer and neurodegenerative, cardiovascular, gastrointestinal and respiratory disorders. Mitochondrial calcium signaling plays a crucial role in energy production and metabolic adaptation; yet when dysregulated, it promotes ROS generation, membrane permeabilization and cell death, all of which further amplify inflammation. Structural and functional mitochondrial messengers, including mtDNA fragments and mitochondria-derived vesicles, also contribute to intercellular communication, enhancing immune activation or driving chronic inflammation depending on their context. Therapeutically, mitochondria are emerging as promising targets to counteract inflammation. Investigational strategies include mitochondrial transplantation, engineered mitovesicles, pharmacological modulators of Ca2 + flux, antioxidants, and agents that restore mitochondrial biogenesis and metabolism. By reestablishing mitochondrial integrity, these interventions aim to reduce inflammatory signaling, restore cellular homeostasis, and slow disease progression.
conclusionsThis review underscores mitochondria as both initiators and regulators of inflammatory processes across multiple diseases, highlighting their dual role as drivers of pathology and as promising therapeutic targets. A deeper understanding of mitochondrial signaling, mitochondrial messengers, and inter-organelle communication will be essential for developing effective mitochondria-based therapies to mitigate inflammation and improve patient outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.